Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2014-12-18. The firm is focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. Its Chemical Induction of Dimerization (CID), technology platform is designed to enable control of components of the immune system in real time. CID consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, instead of by natural upstream signals. The company has developed two such switches: an activation switch, designed to stimulate activation, proliferation and persistence of the immunotherapy cells and provide other immunomodulatory benefits, and a safety switch, designed to initiate programmed cell death, or apoptosis, of the immunotherapy cell.

Industry: Pharmaceutical Preparations Peers: Allarity Therapeutics Inc Windtree Therapeutics Inc /entities/rdgad BioRestorative Therapies Inc Decoy Therapeutics Inc Canton Strategic Holdings Inc Lixte Biotechnology Holdings Inc LogicBio Therapeutics, Inc. ProtoKinetix Inc